– Enrollment continues in second cohort of EnACT research of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Information and Security Monitoring Board (DSMB) analysis of security and efficacy information from second cohort anticipated Q3 2021 –
– MAT2501 (oral amikacin) superior into preclinical toxicology and efficacy research; completion of Part 1 SAD research in wholesome volunteers anticipated by finish of 2021 –
– Matinas to host digital R&D Day on June 17, 2021 to focus on LNC platform and associated packages –
– Information from ENHANCE-IT research of LYPDISO™ towards Vascepa® reported in Q1 2021 assist continued growth of LYPDISO as a possible best-in-class prescription-only omega-3 for cardiovascular danger discount; partnership course of ongoing –
– Administration to host convention name in the present day, Monday, Might 10th, at 8:00 a.m. ET –
BEDMINSTER, N.J., Might 10, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a biopharmaceutical firm targeted on enhancing the intracellular supply of essential therapeutics by its paradigm-changing lipid nanocrystal (LNC) supply platform, in the present day reported monetary outcomes for the primary quarter ended March 31, 2021, together with a company replace.
First Quarter Highlights and Wanting Forward
- Affected person enrollment in Cohort Two of the EnACT research (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) has reached roughly 70 %; DSMB analysis of full security and efficacy information from Cohort Two is anticipated within the third quarter of 2021.
- The Firm has superior MAT2501 into preclinical toxicology and efficacy research, with the objective of finishing a Part 1 single ascending dose (SAD) pharmacokinetic research in wholesome volunteers by the tip of 2021. The Firm expects to provoke a Part 2 program in cystic fibrosis sufferers with nontuberculous mycobacterial infections in 2022 following profitable completion of the Part 1 SAD research.
- Following the announcement of its collaboration with the Nationwide Institutes of Allergy and Infectious Illness (NIAID) in December 2020 to create and consider oral formulations of Gilead’s antiviral remdesivir, the Firm lately ready and delivered a number of formulations to NIAID and expects to obtain information from the primary in vitro research within the close to time period.
- The Firm is happy to announce that it’s going to maintain a digital R&D Day on June 17, 2021. The administration staff plans to offer an summary of the Firm’s LNC platform, together with an in depth dialogue on the platform’s scientific packages.
- The method of figuring out and securing a number of companions for LYPDISO is ongoing, with events globally, together with in the US, European Union and China.
“We’re excited by the alternatives forward for our LNC platform and related drug candidates, and have made significant progress because the starting of 2021,” commented Jerome D. Jabbour, Chief Govt Officer of Matinas. “Particularly, we proceed to advance MAT2203 in cryptococcal meningitis by Cohort 2 of the EnACT trial in direction of its subsequent DSMB assessment, which is anticipated within the third quarter of 2021. We imagine that Cohort 2 information will additional validate the LNC platform and spotlight its means to facilitate oral bioavailability and carry molecules safely and successfully throughout the blood-brain barrier in combating this lethal invasive fungal an infection. We can even take the chance to current these information to the U.S. Meals and Drug Administration in discussions about additional accelerating growth of MAT2203. As well as, we now have superior MAT2501 into preclinical toxicology and efficacy research, with the objective of creating the primary oral aminoglycoside for the therapy of nontuberculous mycobacterial infections, in addition to gram damaging bacterial infections. Lastly, we proceed to increase the appliance of the LNC platform with our collaborations with Genentech and with the NIAID in creating an oral formulation of Gilead’s remdesivir.”
First Quarter 2021 Monetary Outcomes
Money, money equivalents and marketable securities at March 31, 2021, have been roughly $60.7 million, in comparison with $58.7 million at December 31, 2020.
In July 2020, the Firm entered into an At-The-Market Gross sales Settlement (Gross sales Settlement) with BTIG, LLC (BTIG), pursuant to which the Firm might provide and promote, every now and then, by BTIG, shares of its widespread inventory having an combination providing worth of as much as $50 million, topic to sure limitations on the quantity of widespread inventory which may be supplied and offered by the Firm set forth within the Gross sales Settlement. Through the first quarter of 2021, BTIG offered roughly 3 million shares of the Firm’s widespread inventory underneath the Gross sales Settlement producing internet proceeds to the Firm of roughly $5.6 million.
Based mostly on present projections, the Firm believes that money readily available is adequate to fund operations into 2024.
For the primary quarter of 2021, internet loss attributable to widespread shareholders was $5.2 million, or a internet lack of $0.03 per share (primary and diluted). These outcomes are similar to these of the primary quarter of 2020.
Analysis and growth bills for the primary quarter of 2021 have been $3.2 million, in comparison with $4.1 million for a similar interval in 2020. The lower was primarily because of the completion of the ENHANCE-IT research of LYPDISO in January 2021.
Common and administrative bills for the primary quarter of 2021 have been $3.1 million, in comparison with $2.3 million in the identical interval in 2020. The rise was primarily resulting from larger compensation expense associated to the train of inventory choices throughout the first quarter of 2021.
*Vascepa® is a registered trademark of the Amarin group of firms.
Convention Name and Webcast Particulars
The Firm will host a reside convention name and webcast to debate these outcomes in the present day, Monday, Might 10, 2021, at 8:00 a.m. ET.
To take part within the name, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference convention ID 13719092. The reside webcast will probably be accessible on the Investors part of Matinas’ web site, www.matinasbiopharma.com, and archived for 90 days.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical firm targeted on enhancing the intracellular supply of essential therapeutics by its proprietary lipid nanocrystal (LNC) supply platform. Firm management has a deep historical past and data of drug growth and is supported by a world-class staff of scientific advisors.
Matinas is creating a portfolio of merchandise primarily based upon its proprietary LNC drug supply platform, which might remedy complicated challenges regarding the secure and efficient intracellular supply of each small and bigger, extra complicated molecules.
MAT2203 is an oral, LNC formulation of the well-known, however extremely poisonous, antifungal drugs amphotericin B, primarily used to deal with severe invasive fungal infections. MAT2203 is at present in a Part 2 open-label, sequential cohort research (EnACT) in HIV-infected sufferers with cryptococcal meningitis. EnACT is at present enrolling sufferers in its second cohort, with the subsequent DSMB analysis of security and efficacy information anticipated to happen within the third quarter of 2021.
MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic drugs amikacin, primarily used to deal with power and acute bacterial infections. The Firm has been awarded as much as $3.75 million from the Cystic Fibrosis Basis (CFF) to assist growth of MAT2501 towards a sign to deal with nontuberculous mycobacterial (NTM) lung illness, together with infections in sufferers with cystic fibrosis (CF).
Every of MAT2203 and MAT2501 has obtained Certified Infectious Illness Product (QIDP) and Orphan Drug designations which, upon approval, might probably present as much as twelve years of regulatory advertising exclusivity for every product.
LYPDISO™, the Firm’s product candidate supposed for the therapy of cardiovascular and metabolic situations, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, lately introduced information from the ENHANCE-IT research, a head-to-head crossover research evaluating LYPDISO vs. Vascepa in sufferers with elevated triglycerides. Information demonstrating superior ranges of eicosapentaenoic acid (EPA) within the blood with LYPDISO assist the potential superior cardioprotective impact of LYPDISO vs. Vascepa. The Firm has initiated a course of to identification and safe a possible accomplice to proceed growth of LYPDISO towards a cardiovascular outcomes indication.
Ahead Wanting Statements
This launch comprises “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995, together with these regarding the LNC platform supply know-how, the Firm’s strategic focus and the longer term growth of its product candidates, together with MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of scientific research, the anticipated timing of regulatory interactions, the Firm’s means to establish and pursue growth and partnership alternatives for its merchandise or platform supply know-how on favorable phrases, if in any respect, and the flexibility to acquire required regulatory approval and different statements which are predictive in nature, that depend on or discuss with future occasions or situations. All statements aside from statements of historic reality are statements that may very well be forward-looking statements. Ahead-looking statements embrace phrases corresponding to “expects,” “anticipates,” “intends,” “plans,” “might,” “believes,” “estimates” and related expressions. These statements contain recognized and unknown dangers, uncertainties and different elements which can trigger precise outcomes to be materially completely different from any future outcomes expressed or implied by the forward-looking statements. Ahead-looking statements are topic to quite a few dangers and uncertainties, together with, however not restricted to, our means to acquire further capital to satisfy our liquidity wants on acceptable phrases, or in any respect, together with the extra capital which will probably be obligatory to finish the scientific trials of our product candidates; our means to efficiently full analysis and additional growth and commercialization of our product candidates; the uncertainties inherent in scientific testing; the timing, price and uncertainty of acquiring regulatory approvals; our means to guard the Firm’s mental property; the lack of any government officers or key personnel or consultants; competitors; modifications within the regulatory panorama or the imposition of rules that have an effect on the Firm’s merchandise; and the opposite elements listed underneath “Threat Elements” in our filings with the SEC, together with Varieties 10-Ok, 10-Q and 8-Ok. Buyers are cautioned to not place undue reliance on such forward-looking statements, which converse solely as of the date of this launch. Besides as could also be required by regulation, the Firm doesn’t undertake any obligation to launch publicly any revisions to such forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. Matinas BioPharma’s product candidates are all in a growth stage and should not obtainable on the market or use.
|Matinas BioPharma Holdings Inc.|
|Condensed Consolidated Stability Sheets|
|March 31, 2021||December 31, 2020|
|Money and money equivalents||$||23,382,743||$||12,432,481|
|Restricted money – safety deposits||136,000||136,000|
|Pay as you go bills and different present property||2,333,225||2,739,791|
|Complete present property||63,135,665||61,554,845|
|Leasehold enhancements and tools – internet||1,465,303||1,523,950|
|Working lease right-of-use property – internet||3,149,744||3,276,639|
|Finance lease right-of-use property – internet||45,992||58,007|
|In-process analysis and growth||3,017,377||3,017,377|
|Restricted money – safety deposits||200,000||200,000|
|Complete non-current property||9,214,904||9,412,461|
|LIABILITIES AND STOCKHOLDERS’ EQUITY:|
|Working lease liabilities – present||364,566||391,498|
|Financing lease liabilities – present||29,396||30,853|
|Complete present liabilities||2,221,352||3,567,621|
|Deferred tax legal responsibility||341,265||341,265|
|Working lease liabilities – internet of present portion||3,214,714||3,304,063|
|Financing lease liabilities – internet of present portion||17,134||23,660|
|Complete non-current liabilities||3,573,113||3,668,988|
|Sequence B Convertible most popular inventory||3,673,176||3,797,705|
|Extra paid-in capital||175,189,608||167,192,003|
|Gathered different complete revenue/(loss)||136,406||228,172|
|Complete stockholders’ fairness||66,556,104||63,730,697|
|Complete liabilities and stockholders’ fairness||$||72,350,569||$||70,967,306|
|Matinas BioPharma Holdings, Inc.|
|Condensed Consolidated Statements of Operations and Complete Loss|
|Three Months Ended March 31,|
|Contract analysis income||$||33,333||$||–|
|Prices and bills:|
|Analysis and growth||3,241,432||4,086,883|
|Common and administrative||3,145,010||2,259,631|
|Complete prices and bills||6,386,442||6,346,514|
|Loss from operations||(6,353,109||)||(6,346,514||)|
|Sale of New Jersey internet working loss||1,328,470||1,073,289|
|Different revenue, internet||68,319||227,327|
|Most well-liked inventory sequence B accrued dividends||(210,900||)||(170,700||)|
|Internet loss attributable to widespread shareholders||$||(5,167,220||)||$||(5,216,598||)|
|Internet loss obtainable for widespread shareholders per share – primary and diluted||$||(0.03||)||$||(0.03||)|
|Weighted common widespread shares excellent – primary and diluted||203,871,820||191,671,153|
|Different complete (loss)/revenue, internet of tax|
|Unrealized (loss)/good points on securities available-for-sale||(91,766||)||523,246|
|Different complete (loss)/revenue, internet of tax||(91,766||)||523,246|
|Complete loss attributable to stockholders||$||(5,048,086||)||$||(4,522,652||)|
Investor and Media Contacts
Supply: Matinas BioPharma Holdings, Inc.